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In a double-blind, randomized, parallel-group clinical trial, 340 asthmatic patients aged 12-70 years received 
budesonide 400 ,ug once daily in the morning, budesonide 400 ,ug once daily in the evening, budesonide 200 pg 
twice daily or placebo, for 12 weeks in addition to inhaled short-acting &agonists used as required (p.r.n.). 
Budesonide was given as Pulmicort Turbohaler. 
Peak expiratory flow rate (PEFR) increased by 20 to 30 1 min - ’ in each of the active treatment groups, 
significantly more than in the placebo group (P<O.Ol). There were no significant differences between the active 
treatment groups. Symptom improvement and decreased &agonist use reflected the PEFR data. Incidences 
of adverse events in the active treatment groups were similar to those observed in the placebo group. 
Budesonide 400 pug given once daily morning or evening is equieffective with the same total daily dose given 
twice daily in the treatment of mild to moderate stable asthmatics. 
Introduction 
Recent guidelines for the management of asthma 
emphasize the need to initiate prophylactic medica- 
tion with an inhaled steroid if a patient needs to take 
an inhaled short-acting &agonist more than three 
times a week (1,2) or once a day (3). It is, moreover, 
widely recognized that poor compliance with inhaled 
therapy is an important cause of persistent morbidity 
from asthma (4). Use of a device with high 
acceptability - Turbohaler (5) - coupled with a con- 
venient once-daily regimen should favour good com- 
pliance (6). A previous study (7) showed that 
budesonide (Pulmicort Turbohaler, Astra) 4OOpg 
once daily, taken in the evening, was superior to 
placebo in the control of mild to moderate asthma. 
However, the earlier study left unanswered the ques- 
tions of whether 400 lug once a day was as effective as 
200,ug twice a day, and whether the time of day for 
administration of the single daily dose was of import- 
ance. The present study addressed these questions. 
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Methods 
PATIENTS 
Patients aged 12-70 yr with mild to moderate 
stable asthma and documented response to a 
&-agonist were eligible, provided their peak expira- 
tory flow rate (PEFR: recorded with a mini-Wright 
peak flow meter; Clement Clarke Int. Ltd.,) was 
260% of predicted when first seen and after one 
week’s run-in. During the run-in, the patient had to 
have used inhaled &agonist and to have had asthma 
symptoms (score of 2 1 on a O-3 scale) on at least 2 
of the last 5 days. The patients also had to demon- 
strate competence in the use of Turbohaler and the 
peak flow meter. 
Patients were ineligible if they had received long- 
term glucocorticosteroids in the previous 6 months, 
short courses of glucocorticosteroids by any route in 
the past 2 months (except nasal steroids, where the 
period was 1 month), had exacerbation of asthma in 
the past 2 months or used cromoglycate or nedocro- 
mil in the past 2 months. 
A need for nebulized &agonist, a current respira- 
tory infection or one treated in the past 6 weeks, 
other concomitant respiratory diseases, symptomatic 
allergy or a predicted seasonal allergy during the 
study rendered the patient ineligible. 
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Table I Patient characteristics at receipt of randomized treatment 
Puhnicort Twice 
Turbohaler Morning Evening daily 
dose ~OPug 4OOM 200 Pug Placebo 
Number 
Malesfemales 
Weight (kg) 
Height (cm) 
Age 64 
Duration of asthma (yr) 
Most recent exacerbation 
(yr agO) 
PEFR (a.m.)* (1 min-‘) 
(p.m.)? (1 mini ‘) 
Symptomsf (night) 
(day) 
&-agonist uses (night) 
(day) 
84 85 
44:40 42:43 
71 (16) 67 (14) 
167 (10) 165 (10) 
36 (16) 36 (17) 
12 (12) 11 (9) 
1.0 (1.7) 1.6 (4.2) 
383 (99) 
403 (98) 
0.87 (0.54) 
1.11 (0.57) 
1.25 (1.24) 
3.41 (3.06) 
376 (101) 
391 (102) 
0.83 (0.68) 
1.04 (0.52) 
0.96 (1.04) 
3.37 (3.09) 
86 
42144 
68 (16) 
167 (11) 
36 (17) 
9 (8) 
1.6 (2.2) 
372 (96) 
395 (100) 
0.89 (0.60) 
1.03 (0.63) 
1.25 (1.49) 
3.34 (2.68) 
85 
50:35 
71 (13) 
168 (10) 
40 (18) 
11 (10) 
1.7 (2.5) 
386 (99) 
404 (108) 
0.88 (0.68) 
1.11 (0.66) 
1.17 (1.27) 
3.33 (2.61) 
Values are means (SD) 1: recorded on waking, 2: recorded on going to bed, 3: O-3 scale, 4: 
actuations, 14 relate to diary card data during the run-in. The mean PEFR was 379 1 min-’ 
(morning) which was 80% of predicted normal for these patients, and 398 1 mir-’ (84% 
predicted normal) for the evening diary card measurements. The mean PEFR at clinic visit 2 
was 403 1 min-’ (85% predicted): . 
STUDY AND DESIGN 
This was a randomized double-blind, placebo con- 
trolled, multi-centre trial with four parallel treatment 
groups. Following a 1 week (minimum 5 days) run-in 
when patients continued on their current medication, 
they were randomized to receive budesonide 400,ug 
once daily in the morning (‘morning’ group), budes- 
onide 400,ug once daily in the evening (‘evening’ 
group), budesonide 2OOpg twice daily i.e. in the 
morning and evening (‘twice daily’ group) or placebo 
twice daily (‘placebo’ group). All patients received 
coded Turbohaler inhalers for morning and evening 
use, containing lactose as placebo where appropriate 
to maintain blindness. The schedule treatment dura- 
tion was 12 weeks * 7 days. Compliance was assessed 
from diary cards, on which patients recorded the time 
of administration of the study medication. All 
patients were treated by their General Practitioner, 
and all gave written informed consent to participate 
in this study which was approved by an Ethics 
Committee independent of the sponsor. 
Inhaled, short-acting &agonists were allowed on 
an as required (p.r.n.) basis, and their use recorded 
on diary cards. Each patient had to continue using 
the same /?,-agonist and inhaler device throughout. 
Nebulized &agonists, cromoglycate, nedocromil, or 
any non-trial glucocorticosteroid were prescribed. 
Diary cards were completed every morning and 
evening by all patients to record asthma symp- 
toms (Scale: O=none to 3=severe), PEFR, time of 
taking the study medication and &agonist use. 
Data recorded in the morning related to time in 
bed (‘night’). At clinic visits every 4 weeks, the 
Investigators checked the diary cards and recorded 
any adverse events or changes in concomitant 
medication. 
ANALYSIS 
To detect a 5% difference in PEFR between any 
pair of treatments assuming that the SD of a change 
is 10% of the predicted normal value requires 65 
patients per group (PcO.05, 80% probability, t-test). 
This corresponds to detecting differences with 
regards to changes in asthma symptoms between 
any two groups of about 0.2 scale points assuming 
a standard deviation of 0.4 (on a O-3 scale). 
The primary efficacy variables were PEFRs (best of 
three always taken) and asthma symptoms on diary 
cards. Averages over time-intervals were calculated 
for the run-in, weeks 1 and 2, 3 and 4, 5 and 6,7 and 
8, 9 and 10 and 11 and 12. Data are presented for 
intention-to-treat (all patients treated) analyses with 
last value extended. 
Statistical tests were used to compare changes 
from baseline in the four treatment groups (t-test). 
Absolute values are shown as means (SD) and changes 
as mean changes & standard error means. The prin- 
cipal analyses are from the run-in to the end of the 
12-week trial (Tables 24). 
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Table 2 Peak expiratory flow rate at the start and end of treatment 
Pulmicort Morning 
Turbohaler dose 400/% 
Evening 
400 Pg 
Twice daily 
200 P’g Placebo 
PEFR measured in the morning 
Baseline 383 
[80%] 
Increase 26 f 5** 
PEFR measured in the evening 
Baseline 403 
[85%] 
Increase 21 f 5** 
316 372 386 
[80%] [79%] [SO%] 
28 f 6** 31 f s*** 6f5 
391 395 404 
[84%] [840/o] [84%] 
24 f 6** 23 f 6** 2fl 
Values are shown in 1 min- ’ [and % predicted normal] for the run-in (start) and weeks 11-12 
(after treatment). **P<O.Ol, ***P<O.O05 compared with placebo. Increases in PEFR are 
mean f sahf. 
Table 3 Asthma symptoms at the start and end of treatment 
Puhnicort 
Turbohaler dose 
Morning 
400 I% 
Evening 
400 Pug 
Twice daily 
200% Placebo 
Symptoms during the night 
Baseline 0.87 
Decrease 31% 
0.27 f 0.08 
Symptoms during the day 
Baseline 1.11 
Decrease 32% 
0.35 f 0.08 
0.83 0.89 0.88 
16% 38%** 6% 
0.13+0.09 0.34 f 0.06 0.05 + 0.09 
1.04 1.03 1.11 
26% 28% 11% 
0.27 f 0.09 0.29 f 0.07 0.19 f 0.08 
Values are shown as symptom severity scores (O-3 scale) for the run-in (start) and weeks 11 and 
12 (after treatment). **P<O.Ol vs. placebo. Decreases are shown as % and mean f SEM scale 
scores. 
Table 4 &-agonist use at the start and end of treatment 
Puhnicort 
Turbohaler dose 
Morning 
400 Pi? 
Evening 
4f)oPg 
Twice daily 
2OOPtz Placebo 
&agonist use at night 
Baseline 1.25 
Decrease 30%* 
0.37 f 0.14 
&agonist use during the day 
Baseline 3.41 
Decrease w/c** 
1.50 + 0.24 
0.96 1.25 1.17 
-1% 38%** -11% 
-0.01 f 0.14 0.48 f 0.13 -0.13 f 0.19 
3.37 3.34 3.33 
30% 27% 18% 
1.02 f 0.26 0.91 f 0.23 0.59 f 0.2 1 
Values are shown as doses per day or per night. *P<O.O5, **P<O.Ol vs. placebo. Decreases are 
shown as % and doses/day, mean f SEM. 
Results deterioration of asthma, and 43 were lost to 
Three hundred and forty-four patients were ran- follow-up or withdrew for other reasons. 
domized; 340 received treatment and 265 completed Patient characteristics for the 340 analysed patients 
the 12 week study. Of the remaining 75, 14 with- at randomization are shown in Table 1. Patients 
drew because of adverse events and 18 because of received the study drugs on average for 12.8 
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Weeks 1 and Z- 3and4 5and6 I and 8 9 and 10 11 and 12 
Weeks 1 and 2 3and4 5and6 7and8 9 and 10 11 and 12 
Fig. I Increases in peak flow (PEFR) for each treatment group from diary cards completed in weeks 1 and 2, 3 and 4, 5 
and 6, 7 and 8, 9 and 10 and 11 and 12 compared with run-in. ( q ) 400 pg morning, (69) 400 pug evening, ( W) 2OOpg b.d., 
(0) placebo. *P<O.OS, **P<O.Ol, ***P<O.OOl. 
(morning), 12.7 (evening), 12.8 (twice daily) and 12.6 
(placebo group) weeks. The mean times of drug 
intake were 08.19 h and 09.23 h. Patients reported 
missing taking study drugs on 2.8% of scheduled 
occasions. 
PEAK EXPIRATORY FLOW RATE 
Morning and evening peak expiratory flow rates 
(PEFR) increased to a significantly greater extent in 
patients receiving each budesonide regimen than in 
patients receiving placebo (all BO.01). There were 
no significant differences between the budesonide 
groups (4OOyg morning, 4OOpg evening or 200 pg 
twice daily) (Fig. 1) 
Mean values recorded on diary cards are shown in 
Table 2. Absolute and calculated % predicted PEFR 
increased similarly for all three active budesonide 
regimens, but not for placebo. The mean differences 
between active and placebo in the increment in PEFR 
measured in the morning from the run-in to weeks 11 
and 12 were 20.2 1 min- ’ for budesonide 4OOpg in 
the morning (P<O.O05), 22.3 1 min-’ for 4OOpg 
budesonide in the evening (PcO.005) and 24.8 1 
min-’ for 2OOpg budesonide twice daily (P<O.OOl). 
The corresponding values for peak flow measured in 
the evening were 19.3 (P<O.Ol), 22.2 (BO.005) and 
20.9 (BO.01) 1 min-‘. 
ASTHMA SYMPTOMS 
Asthma symptoms improved in all treatment 
groups over the 12-week study. The improvements 
were from a relatively low level of recorded symp- 
toms (Table 1) and although the improvements were 
consistently greater for the three active groups than 
for placebo, these differences did not generally attain 
statistical significance (Table 3). 
p,-AGONIST USE 
In general the three groups receiving budesonide 
used less &agonists on a p.r.n. basis than the group 
receiving placebo (Table 4). Although these results 
showed appreciable variability, daytime &agonist 
use fell by around 1 dose per day (approximately 
30%) in all budesonide groups from a starting level of 
about 3.4 doses per day. 
In the morning and twice-daily groups nocturnal 
/3,-agonist use also fell by around 30%; in the evening 
group, &-agonist use at night did not change from a 
level which was already lower than in other groups 
during the run-in. 
TIME COURSE OF CHANGES 
Figure 2 shows the changes in the variables from 
run-in to weeks 3 and 4 and to weeks 11 and 12. 
Whilst changes in symptoms and p,-agonist use were 
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Night-time 
Weeks 
Improved o’3 
asthma 
symptoms 0.2 
(O-3 scale) 0.1 t 
Day-time 
Reduced 
PZ use 
(doses) 
Fig. 2 Changes in PEFR, asthma symptom severity and /$ use after 4 weeks and 12 weeks treatment with budesonide 
400 ,ug once daily in the morning (A), 400 pg once daily in the evening ( l ), 200 pg twice daily ( 0) or placebo ( n ). Changes 
are shown separately for night-time (recorded on rising: morning peak flow) and day-time (recorded on retiring: evening 
PEFR). 
essentially complete after 4 weeks, improvements in 
PEFR with budesonide were consistently greater 
after 12 weeks. 
SAFETY AND TOLERABILITY 
In all, 324 patients were evaluable for safety. Of the 
16 not evaluable, 13 were lost to the treatment week 
4 follow-up clinic visit, two withdrew a few days after 
randomization and all records were lost for one 
patient. The frequency of occurrence of adverse 
events was the same in the budesonide and placebo 
groups. In the three budesonide groups, 98 (40%) 
patients reported 152 adverse events, and in the 
placebo group 34 (43%) patients reported 59 adverse 
events. 
Around 20% of the reported adverse events were 
identified from patients’ comments on diary cards, 
and the remainder from clinic visit reports. Details of 
all serious adverse events and adverse events leading 
to withdrawal are given in Table 5. Other events 
reported with a frequency >2% were: respiratory 
infection (budesonide 1 lo,, placebo 20%), aggra- 
vation of asthma (placebo 8%), coughing (placebo 
4%), bronchitis (placebo 3%), headache (budesonide 
7%, placebo So/), dyspepsia (placebo 3%), accident 
and/or injury (placebo 5%). An extensive miscellany 
of other reports were found. The distribution of 
withdrawals was significantly different between 
groups (PcO.05, ?-test) only with regard to deterio- 
ration of asthma which occurred most commonly in 
the placebo group (Table 5). 
Discussion 
Pulmicort (budesonide) Turbohaler in a total daily 
dose of 4OOpg is equally effective and well tolerated 
when given once daily as when given in two divided 
doses for the treatment of mild to moderate stable 
asthma. 
This study confirms and extends the observations 
made previously (7) that budesonide 4OOpg once- 
daily in the evening is superior to placebo, to show 
that the once-daily dose may be given in the morning 
or evening, and that once daily administration is 
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Table 5 Reasons for withdrawal 
Pulmicort 
Turbohaler dose 
Morning Evening 
400 Pug 400,a 
(n=84) (n=85) 
Twice daily 
200 Pg 
(n=86) 
Placebo 
(n=85) 
Adverse events 
Serious adverse events* 
Withdrawals due to adverse events 
0 3*** 2t 21 
55 2ll 511 2** 
Other reasons for withdrawal 
Asthma deteriorated 
Others (lost to follow-up) 
Total withdrawals 
1: (10) &l) 1: (5) 1; mt 
22 14 17 23 
*According to protocol definition. ***pleural pain; angioneurotic oedema; bleeding gastric 
ulcer. TAppendicitis (2). SPneumonia; asthma deterioration. A causal relationship with the 
study medication was considered ‘unlikely’ by the Investigators in each case. §Lump in 
throat; sinusitis; chest tightness, fatigue, tremor, itching; fractured ankle; headache, coughing. 
womiting, shaking; pleural pain. IIDizziness, nausea; rash; acne; mouth ulcers; bad dreams, bad 
temper, tearful. **Wheeze, cough; pneumonia. ttIncludes one for whom the record book was 
lost. 
equieffective with the same total daily dose given in 
divided doses. All dosage schedules for budesonide 
were equivalent in efficacy and superior to placebo. 
The magnitudes of the increases on PEFR 
measured both morning (around 30 1 min- ‘) and 
evening (around 25 1 min- ‘) were similar in the 
present and the previous study (7), patient character- 
istics also being similar in the two studies. Patients’ 
PEFRs were relatively high at entry (evening PEFR 
around 400 1 min- ‘: Table I), reflecting the fact that 
relatively mild asthmatic patients were eligible for 
this study in General Practice; one consequence of 
this is that the potential for improvement in PEFR is 
limited. It is interesting that PEFR appeared to 
increase after the first 4 weeks of treatment, through 
improvements in asthma symptoms and bronchodi- 
lator use were apparently maximal within 4 weeks. 
Patients in both studies were not using inhaled corti- 
costeroids before the start of the study, and in both 
studies &agonist use was about 34 times per day on 
average, well in excess of the recommended frequency 
of use at which inhaled steroid therapy should be 
introduced, i.e. once a day (3) or less (1,2). Moreover, 
reduced bronchodilator use was a less sensitive reflec- 
tion of improved PEFR or asthma symptoms. From 
these two studies, it appears that if PEFR is the 
primary end-point in a trial, a treatment period in 
excess of 4 weeks is mandatory, and recording 
&agonist use as a surrogate end-point for asthma 
symptoms or PEFR could be misleading. 
Asthma symptoms improved in all active treatment 
groups to a greater extent than in the placebo group; 
however scores were low at entry to the trial. Typical 
symptom scores in the run-in, before the institution 
of budesonide or placebo were around 1 by day and 
0.9 by night out of a maximum of 3. A ‘placebo 
effect’ would be predicted on symptoms, and was 
found, more marked by day than by night; since the 
study was designed to detect a difference between 
changes in symptom scores of about 0.2 scale point, it 
is not surprising that changes from a baseline as low 
as 0.9-1.0, while indicating advantages for budes- 
onide, did not always reach statistical significance 
especially as there were concomitant reductions in /3, 
use. Use of a O-10 scale system would not have 
helped (7). It may be that both ‘overuse’ and habitual 
use of &agonists among these patients means that 
they were relatively free of symptoms, although their 
PEFRs were around 80% predicted, at entry. 
Comparing the three active regimens (Fig. 2) does 
not give a clear basis for recommending use of 
budesonide at any particular time of day. Where 
apparent differences exist (e.g. in the failure of the 
evening dose to result in reduce &agonist use: Table 
4), they appear to reflect differences in baseline 
values, and as in this case, are not consistent with the 
earlier study (7). In the previous study, nocturnal 
administration was chosen to give the best chance of 
controlling nocturnal symptoms which were con- 
sidered the most likely to be troublesome; however, if 
such an advantage exists, it is marginal (Fig. 2) over 
other dosage schedules. Evening administration may 
be less preferable on theoretical grounds, to avoid 
exacerbating the physiological diurnal reduction in 
circulating cortisol levels, though it is uncertain 
whether this has any relevance at dosage levels such 
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as 400,&day in adults. On balance, it seems reason- 
able to leave the time of dosing to the individual 
physician. Having established that once-daily admin- 
istration of budesonide is appropriate as initial pro- 
phylactic treatment at 400,~g/day, trial study raises 
two issues which need further study: whether once- 
daily administration is appropriate for higher doses, 
and whether once-daily budesonide administration is 
an option for patients already receiving inhaled 
steroids - including those in whom a dose-reduction 
is possible. 
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